Leaving INTR@PID website

You are leaving INTR@PID Clinical Trials page. This link will take you to a website where our Terms of Use do not apply. Merck KGaA, Darmstadt, Germany has no control over the contents and policies of these sites or resources, and accepts no responsibility for your use of them.

Please Confirm

This website is an information resource intended only for Healthcare Professionals who are interested in information on Clinical Research and clinical trials conducted under a partnership between EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, and GSK.

By clicking "I am a healthcare professional" you are declaring and confirming that you are a Healthcare Professional inside the U.S., and have read and understood this disclaimer.

UROTHELIAL CANCER

Investigational clinical trial in urothelial cancer


UROTHELIAL 152

LOCALLY ADVANCED/ METASTATIC

PHASE 1

MONOTHERAPY


INTR@PID UROTHELIAL 152 (NCT04349280) is a clinical trial assessing the efficacy and safety of bintrafusp alfa for the treatment of locally advanced or metastatic urothelial cancer in patients with disease progression or recurrence following prior chemotherapy.1

Other Study ID:  GSK213152

 Status:

Now Enrolling


What is urothelial cancer?


Bladder cancer is a common type of cancer, with approximately 573,000 people diagnosed worldwide in 2020.2 In the United States and Europe, around 90% of bladder cancers are urothelial cancers, also known as transitional cell carcinoma3,4 Urothelial cancer can also form in other areas of the urinary tract, including the urethra, ureters, and renal pelvis4

There are 4 main sites where urothelial cancer can form4:

1. Bladder: cancer that forms in cells that line the inside of the bladder, which is responsible for storing urine5

2. Urethra: cancer that forms in cells on the inside of the urethra, which is responsible for carrying urine from the bladder and removing it from the body during urination6

3. Ureters: cancer that forms in cells on the inside of the ureters, which are responsible for carrying urine from the kidneys to the bladder7

4. Renal pelvis: cancer that forms in cells on the inside of the renal pelvis, which is responsible for carrying urine from the kidneys to the ureters7

The urinary tract and cancer


  1. ClinicalTrials.gov. GSK Identifier: 213152. A study to evaluate the efficacy and safety of bintrafusp alfa (M7824) monotherapy in metastatic or locally advanced urothelial cancer. Accessed March 8, 2021. https://clinicaltrials.gov/ct2/show/NCT04349280.
  2. Ferlay J, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Accessed 14 May 2021. https://gco.iarc.fr/today.
  3. Wong MCS, et al. Sci Rep. 2018;8:1129.
  4. National Cancer Institute. NCI dictionary of cancer terms. Accessed March 8, 2021. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/urothelial-cancer.
  5. National Cancer Institute. Bladder cancer treatment (PDQ)–patient version. Accessed March 8, 2021. https://www.cancer.gov/types/bladder/patient/bladder-treatment-pdq.
  6. National Cancer Institute. Urethral cancer treatment (PDQ)–patient version. Accessed March 8, 2021. https://www.cancer.gov/types/urethral/patient/urethral-treatment-pdq.
  7. National Cancer Institute. Transitional cell cancer of the renal pelvis and ureter treatment (PDQ)–patient version. Accessed March 8, 2021. https://www.cancer.gov/types/kidney/patient/transitional-celltreatment-pdq.
 

Explore the Knowledge Base